OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
This article was originally published in The Tan Sheet
Former McNeil Consumer Pharmaceuticals exec Stephen Mann says FDA’s approval of OTC Oxytrol poses a challenge to the EU, where Rx-to-OTC switches and the self-care movement face major obstacles. More regulators are weighing drug switches for chronic conditions, consultant Susan Coleman says.
You may also be interested in...
Merck’s Oxytrol for Women has the opportunity to “create the market” for OTC overactive bladder drugs, as well as encourage other switches for chronic, progressive conditions, marketing consultant Joe McGovern says. The transdermal patch product is slated to launch in September.
EU Health Commissioner John Dalli expects the region’s growing health care budgets and economic crisis to lead governments to restructure and impose more responsibility on consumers for health care costs. A self-medication working group launched in France will look at easing Rx-to-OTC switches.
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says